LianBio Acquires China Rights to ReViral's RSV Therapy in $119 Million Deal

LianBio, a Shanghai-Princeton, NJ biopharma, acquired China rights to a novel clinical-stage respiratory syncytial virus (RSV) therapy being developed by ReViral of London. Lian will make a $14 million upfront payment and also pay up to $105 million in milestones, plus royalties. ReViral's sisunatovir is an oral fusion inhibitor being tested in two global Phase II trials: one in children and the other in adult stem-cell transplant patients. Last year, LianBio was founded by Perceptive Investors, a US life science investment firm, to bring assets from Perceptive's portfolio companies to China . More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.